CLNN Clene Inc
Price (delayed)
$5.7
Market cap
$36.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.46
Enterprise value
$47.76M
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new
Highlights
CLNN's EPS has surged by 64% year-on-year and by 52% since the previous quarter
The net income is up by 38% YoY and by 38% QoQ
CLNN's gross margin is down by 8% YoY but it is up by 2.9% from the previous quarter
The equity has plunged by 112% from the previous quarter and by 102% YoY
CLNN's quick ratio has plunged by 91% YoY and by 28% from the previous quarter
Key stats
What are the main financial stats of CLNN
Market
Valuations
Earnings
Shares outstanding
6.47M
Market cap
$36.88M
Enterprise value
$47.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
82.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
108.05
Revenue
$442,000
EBIT
-$25.54M
EBITDA
-$23.38M
Free cash flow
-$27.47M
Per share
Balance sheet
Liquidity
EPS
-$4.46
Free cash flow per share
-$4.28
Book value per share
-$0.08
Revenue per share
$0.07
TBVPS
$6.28
Total assets
$40.33M
Total liabilities
$40.83M
Debt
$32.62M
Equity
-$504,000
Working capital
-$159,000
Debt to equity
-64.72
Current ratio
0.99
Quick ratio
0.77
Net debt/EBITDA
-0.47
Margins
Efficiency
Dividend
EBITDA margin
-5,290.3%
Gross margin
81%
Net margin
-6,890.5%
Operating margin
-8,166.3%
Return on assets
-61.5%
Return on equity
-316%
Return on invested capital
-86.7%
Return on capital employed
-208.3%
Return on sales
-5,778.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLNN stock price
How has the Clene stock price performed over time
Intraday
-15.43%
1 week
-0.87%
1 month
10.68%
1 year
-47.22%
YTD
-3.88%
QTD
-19.94%
Financial performance
How have Clene's revenue and profit performed over time
Revenue
$442,000
Gross profit
$358,000
Operating income
-$36.1M
Net income
-$30.46M
Gross margin
81%
Net margin
-6,890.5%
Clene's operating margin has plunged by 50% YoY and by 30% from the previous quarter
The gross profit has contracted by 48% YoY and by 27% from the previous quarter
The revenue fell by 44% YoY and by 29% QoQ
The net income is up by 38% YoY and by 38% QoQ
Growth
What is Clene's growth rate over time
Valuation
What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
82.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
108.05
CLNN's EPS has surged by 64% year-on-year and by 52% since the previous quarter
The equity has plunged by 112% from the previous quarter and by 102% YoY
The stock's price to sales (P/S) is 87% less than its 5-year quarterly average of 745.7 but 19% more than its last 4 quarters average of 82.0
The revenue fell by 44% YoY and by 29% QoQ
Efficiency
How efficient is Clene business performance
Clene's return on equity has surged by 78% YoY
The ROA has grown by 41% YoY and by 29% from the previous quarter
Clene's return on invested capital has increased by 32% QoQ and by 16% YoY
CLNN's return on sales is up by 19% since the previous quarter
Dividends
What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLNN.
Financial health
How did Clene financials performed over time
CLNN's quick ratio has plunged by 91% YoY and by 28% from the previous quarter
The company's current ratio has shrunk by 89% YoY and by 20% QoQ
The equity has plunged by 112% from the previous quarter and by 102% YoY
The company's debt rose by 3% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.